Brazil’s Eurofarma acquires BPH drug Aclosan from Gobbi Novag in Argentina



Brazil-based multinational company (MNC) Eurofarma purchased for the Argentina market local firm Gobbi Novag’s Aclosan (tamsulosin hydrochloride), an established generic for the treatment of benign prostatic hyperplasia (BPH). Industry insiders estimate the transaction at ARS 80 million (USD 1 million), which Gobbi Novag will use to bolster its production facilities with the aim of focusing on the radiology area.

The deal is part of Eurofarma’s plan to increase its foreign sales to 30% of the total by 2022, which last year accounted for BRL 5.6 million (USD 1.1 million). In addition, the firm could synergize Aclosan with bladder carcinoma treatment Immucothel (immunocyanin).

Reference:

Related news
The Volume Based Procurement (VBP) Office issued details of a third batch of drugs set to enter the VBP program, as well as new tendering terms and conditions.
The Liaoning provincial drugs and medical consumables centralized procurement platform published a list of drugs suspended from online procurement.
Japanese pharmaceutical company Astellas is reportedly planning to open a representative office in Argentina, sharing a Buenos Aires building with other firms such as Bristol-Myers Squibb (BMS).
Argentina’s Comprehensive Medical Attention Program (PAMI), the largest healthcare program in the country, today adopted a list of medicines that will be provided to patients free of charge, according to a declaration from President Alberto Fernández.
Peru’s Ministry of Health (MINSA) last week released the list of generic drugs that private pharmacies must offer to patients, part of an effort to improve healthcare access.
Recent news
Cuba’s state-run BioCubaFarma and UK’s SG Innovations this week announced the creation of biopharmaceutical joint venture (JV) Biofarma Innovations, which will be based in the United Kingdom.
Hutchison China MediTech Ltd (Chi-Med; Nasdaq/AIM: HCM) released its H1 2020 financial report, with updates on key clinical and commercial developments. Group revenues reached USD 107 million, up 4.5% year-on-year(YOY).
China-based biotech BeiGene Ltd (Nasdaq.BGNE; HKEX.06160) released financial results for Q2 2020.
US-based biotech Biogen Inc., (Nasdaq.BIIB) committed to a deal worth over USD 2 billion to add an innovative Parkinson’s disease therapy to its pipeline for US and China development.
Bolivia’s Ministry of Health (MoH) this week announced it is taking measures to ensure the free provision of treatments used to treat COVID-19.
Mexico’s Chancellor Marcelo Ebrard Casaubón last week revealed that the government is in talks with the governments of China, Germany, and the US, aimed at signing memoranda of understanding (MoUs) to secure early access to the SARS-CoV-2 vaccines being developed by their companies, particularly those that have entered Phase III.
Analytics Snapshot


Analytics Snapshot